Introduction
Non-alcoholic fatty liver disease (NAFLD) is an important manifestation of obesity and the metabolic syndrome (1, 2) . With increasing rates of obesity, NAFLD has become one of the most common causes of liver dysfunction worldwide, affecting 20-30% of the population in developed countries (3) (4) (5) .
NAFLD is defined as fatty infiltration affecting >5% of liver tissue (in the absence of excessive alcohol consumption) and can range in severity from simple steatosis (fat without hepatocellular injury), to steatohepatatitis (NASH; fat with hepatocellular injury and hepatic inflammation), which can progress to fibrosis and cirrhosis (2, 6) . The natural history of NAFLD is variable with simple steatosis having a good long term prognosis with low rates of liverrelated morbidity (7) (8) (9) (10) . However, approximately 30% of patients with NASH will progress to cirrhosis (10, 11) and be at risk of subsequent life threatening liver related complications such as hepatocellular carcinoma, portal hypertension and liver failure (12) (13) (14) (15) .
It is important to identify patients with advanced fibrosis and cirrhosis to screen for liver-related complications. Several previous studies have identified clinical and laboratory factors that are associated with fibrosis in patients with NAFLD including: age, the presence of diabetes, raised BMI, AST/ALT ratio, platelet count, serum albumin and ferritin (16) (17) (18) . Some of these variables are included in simple non-invasive scoring systems to predict fibrosis in NAFLD such as the FIB-4 score and the NAFLD fibrosis score (17, 19, 20) . When used clinically these scores have excellent negative predictive ability and can reliably exclude advanced fibrosis (21, 22 ).
Serum immunoglobulins are tested routinely as part of the investigation of subjects with suspected liver disease and a polyclonal increase in serum immunoglobulin levels is frequently seen in patients with liver cirrhosis (23) . In addition, characteristic patterns of elevation in serum immunoglobulins are observed in specific liver diseases such as autoimmune hepatitis (raised IgG), primary biliary cirrhosis (raised IgM) and alcoholic liver disease (raised IgA).
These can be used clinically to aid diagnosis (24, 25) . In alcoholic liver disease (ALD) raised serum IgA levels are associated with more advanced liver fibrosis (26) . Deposition of IgA in the liver has also been described in ALD, suggesting it might have a pathogenic role (27). Previous studies have shown that serum IgA levels are increased in subjects with the metabolic syndrome and type 2 diabetes (28, 29).
To date, little is known about how serum immunoglobulin levels are altered in patients with NAFLD. In view of the shared pathogenic mechanisms and similar histological appearances in NAFLD and ALD, we hypothesised that serum IgA will be elevated in subjects with NAFLD, and that higher levels will be seen in those with more advanced fibrosis.
Our aim was to a evaluate serum immunoglobulin levels (IgA, IgG and IgM) in a large cohort of patients with biopsy-proven NAFLD of varying severity to determine how frequently elevated serum immunoglobulin levels occur and whether there are any relationships between immunoglobulin levels and histological or clinical features.
Patients and Methods
This study included consecutive patients with biopsy-proven NAFLD who The NAFLD fibrosis score and FIB-4 score were calculated as previously described (17, 19) .
Percutaneous liver biopsies were performed using a Menghini needle or an 
Results

Patient characteristics
From a total of 405 patients biopsied for NAFLD between 1999 and 2009, 285 patients had serum immunoglobulins measured within 6 months of liver biopsy and were included in the analysis. Eighty-one of the patients also had a follow up liver biopsy. The baseline demographic, clinical and biochemical data for all patients is summarised in Table 1 . One hundred and ten patients (39%) had evidence of simple steatosis and 175 (61%) had evidence of steatohepatitis on biopsy. Patients exhibiting all 5 stages of fibrosis were present in the cohort (see Table 1 Table 1 .
Relationship between serum IgA levels and histology Serum IgA levels were more frequently elevated (>1x ULN) in patients with NASH compared with subjects with simple steatosis (55% vs 31% p<0.001) and the overall median serum levels of IgA were higher in patients with NASH versus those with simple steatosis (
There was a significant progressive increase in the proportion of patients with raised serum IgA levels with increasing stages of fibrosis from 31% for subjects with stage 0 fibrosis to 80% with stage 4 fibrosis (p<0.001, Figure   2A ). If 1.5x ULN was used as the level for an elevated serum IgA then a similar relationship between serum IgA and fibrosis is seen ( Figure 2B ). In addition, there was a significant positive association between serum IgA levels and the stage of fibrosis (p<0.001, See Figure 3A) . A similar relationship was observed between fibrosis and serum IgA/Total immunoglobulin levels (p<0.001, Figure 3B ).
In order to determine whether the positive association between serum IgA levels and NASH was dependent entirely on fibrosis or whether steatohepatitis was independently associated, a separate analysis was conducted including only patients with stage 0 or 1 fibrosis (n=194). In that cohort significantly more patients with histological evidence of NASH had elevated serum IgA levels than subjects with simple steatosis (46% vs 30% p=0.026), suggesting that steatohepatitis is independently associated with raised serum IgA levels. Subjects with elevated serum IgA levels were more likely to have NASH than simple steatosis (74% vs 26% p<0.001).
IgG, IgM and total Immunoglobulins
Serum IgG and total immunoglobulins levels were significantly higher in patients with cirrhosis (stage 4) compared with subjects with stage 0-3 fibrosis (p<0.001 for both, Figure 4A Table 2 . In order to determine which of these factors were independently associated with advanced fibrosis a logistic regression analysis was conducted adjusting for age, gender, BMI, presence of diabetes, gammaglutamyl transferase, platelets, AST/ALT ratio, serum IgA and total serum immunoglobulins. Age, platelets, AST/ALT ratio, BMI and serum IgA were all independently associated with advanced fibrosis (see Table 3 There was no relationship between serum IgG levels or total Immunoglobulin levels and diabetes in patients with NAFLD (p=0.51 and 0.19 respectively).
Serum IgA levels and fibrosis progression Eighty-one patients had a follow-up liver biopsy after a median of 6.4 [3.5-8.9] years. Of these, 29 (36%) progressed by 1 Kleiner stage of fibrosis or more. 
Discussion
It is accepted that serum immunoglobulin levels are frequently increased in patients with cirrhosis and specific elevations of serum immunoglobulins are seen in some liver diseases such as PBC (IgM), autoimmune hepatitis (IgG) and alcoholic liver disease (IgA) (23) (24) (25) . In the present study, we evaluated serum immunoglobulin levels in a large cohort of patients with histologically characterised NAFLD of varying severity. The key findings of the study were that serum IgA levels were elevated in almost half the NAFLD cohort and there was a significant positive relationship between serum IgA levels and fibrosis. Moreover, the serum IgA level was an independent predictor of advanced fibrosis and was included in a model that accurately predicted advanced fibrosis (Kleiner Stage 3-4) in this cohort of patients with NAFLD.
With increasing rates of obesity worldwide, NAFLD has become very common, affecting 20-30% of the population in many developed countries (6).
It is important to identify subjects with advanced fibrosis from this large proportion of the population as they are at the highest risk of liver-related complications (32) . Many studies have looked at factors associated with fibrosis in NAFLD and repeatedly age, AST/ALT ratio, platelet count, the presence of diabetes and BMI and albumin have been shown to be associated with advanced fibrosis (16, 17, (20) (21) (22) . Some of these factors are included in various models to predict advanced fibrosis such as the BARD score, the FIB-4 score and the NAFLD fibrosis score, which can be used clinically to exclude or diagnose advanced fibrosis with reasonable accuracy (16, 17, (20) (21) (22) . Our results show that, in addition to these known factors, serum IgA levels were independently associated with advanced fibrosis. A statistical model (BAAAP score), incorporating BMI, serum IgA, age, AST/ALT ratio, and platelet count showed good diagnostic accuracy for advanced fibrosis (AUROC 0.87). However, it needs to be validated in an external cohort before it can be recommended for clinical use.
In the present study 46% of subjects with NAFLD had an elevated IgA (>1x ULN), whereas 10% had an elevated IgG and 8% an elevated IgM. Previous studies have shown that elevation of serum IgA levels was uncommon in other liver diseases such as hepatitis C, PBC and autoimmune liver disease (25, 33) . It is well known that serum IgA levels are elevated in patients with alcoholic liver disease (26, 27, 29) , but results of the present study suggest that the IgA is also specifically elevated in NAFLD. Therefore, when investigating patients with suspected liver disease, the finding of an elevated IgA should prompt clinicians to consider NAFLD as a diagnosis where there is no history of excessive alcohol consumption.
Approximately 10-30% of patients with NAFLD have NASH, which can progress to cirrhosis (34, 35) . Currently the only effective method of diagnosing NASH is by liver biopsy, but this is invasive and therefore impractical for widespread use. In the present study we found that significantly more patients with an elevated serum IgA level had NASH than simple steatosis (74% vs 26%). Therefore, assessment of serum IgA levels along with other clinical factors might help clinicians determine which patients need a biopsy to confirm NASH. The search for an accurate blood test to noninvasively diagnose NASH is an active area of clinical research.
Eighty one of the patients had follow up liver biopsies in the study and approximately a third of the patients had progression of fibrosis over a median follow up of 6 years. This rate of progression was similar to previous studies (11, 36) . There was a trend to higher serum IgA levels in the patients who had fibrosis progression compared with the non-progressors. As we have demonstrated an association between higher IgA levels and fibrosis and steatohepatitis, it is likely that high IgA levels reflect more severe baseline disease that is more likely to progress. However, the number of patients with follow up liver biopsies was relatively small and so this association should be assessed in a larger cohort of patients with NAFLD.
The cause of raised IgA in patients with NAFLD is unknown. As well as being present in serum, IgA is secreted at high concentrations on mucosal surfaces of protect against external pathogens (37) . A major source of IgA is the gut, where it plays a role in the mucosal immune response against intestinal bacteria (37) . A previous study demonstrated that the intestinal microflora was different in subjects with obesity compared to lean controls, and the alterations were abolished after diet induced weight loss (38) . In addition, structural changes in the intestinal mucosa occur in patients with chronic liver disease that allows translocation of bacteria and bacterial products, such as LPS, to the circulation (39) . Toll-like receptors recognise bacterial products and evoke intense inflammatory reactions that might contribute to the pathogenesis of NASH (15, 40) . Therefore, it is possible that Toll-like receptor stimulation of B cells in response to changes in bacterial microflora and bacterial translocation is responsible for high IgA levels seen in NAFLD. A potential mechanism involving TLR9 has been suggested to cause raised IgA levels in patients with ALD (41) . Further evaluation of the underlying mechanism in NAFLD is warranted.
Previous studies have found high serum IgA levels in subjects with type 2 diabetes and the metabolic syndrome (28, 29). As insulin resistance is a key feature of NAFLD, and the majority of subjects with the metabolic syndrome and type 2 diabetes have steatosis (42), it is not surprising that there is a shared association with elevated serum IgA levels in those conditions. In the present study we found that higher IgA levels were seen in diabetics than non-diabetics after correcting for fibrosis. Diabetes is associated with a low grade chronic inflammatory state, with increased levels of circulating proinflammatory cytokines such as TNFα and IL-6 (15, 43, 44) . Higher serum IgA levels in diabetics might therefore be a marker of higher levels of systemic inflammatory activity. Further studies evaluating serum cytokines and IgA levels in NAFLD might help elucidate the underlying mechanisms and determine the cause-effect relationship.
In conclusion, results from the present study show that serum IgA levels were frequently elevated in patients with NAFLD, with higher levels in subjects with NASH than simple steatosis. In addition, serum IgA levels were an independent predictor of advanced fibrosis in patients with NAFLD. Therefore, along with other clinical features and biochemical results, assessment of the serum IgA might help stage disease in subjects with suspected NAFLD.
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